Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.56 |
| ▸ | CA1 | P00915 | 9/20 | 0.56 |
| ▸ | CA12 | O43570 | 7/20 | 0.56 |
| ▸ | CA9 | Q16790 | 5/20 | 0.56 |
| ▸ | CA7 | P43166 | 4/20 | 0.56 |
| ▸ | CA6 | P23280 | 2/20 | 0.56 |
| ▸ | CA5A | P35218 | 2/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27565494 | 0.81 | CA2 (0.68) | CA2CA1CA12CA9CA7 | |
| SCHEMBL5653047 | 0.79 | CA9 (0.54) | CA2CA1CA12CA9CA7 | |
| SCHEMBL20534987 | 0.79 | CA12 (0.51) | CA2CA1CA12CA9CA7 | |
| SCHEMBL2025236 | 0.79 | KMT2A (0.59) | CA2CA1CA12CA9CA7 | |
| SCHEMBL229506 | 0.78 | CA12 (0.68) | CA2CA1CA12CA9CA7 | |
| SCHEMBL3566466 | 0.78 | CA12 (0.54) | CA2CA1CA12CA9CA7 | |
| Hydrochloric Acid SCHEMBL12006144 | 0.78 | KMT2A (0.58) | CA2CA1CA12CA9CA7 | |
| Water SCHEMBL3952740 | 0.77 | CA12 (0.65) | CA2CA1CA12CA9CA7 | |
| SCHEMBL10953887 | 0.77 | CA12 (0.65) | CA2CA1CA12CA9CA7 | |
| Ammonia Solution, Strong SCHEMBL4593139 | 0.77 | CA12 (0.65) | CA2CA1CA12CA9CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2026-01-29 | — | — | US | claimed |
| EP-4676540-A1 | PANRAS INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2026-01-14 | — | — | EP | claimed |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | claimed |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-11-06 | — | — | US | claimed |
| WO-2025111431-A1 | ANTI-CD7 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | LES LABORATOIRES SERVIER (FR) | 2025-05-30 | — | — | WO | claimed |
| EP-4525925-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | claimed |
| EP-4525927-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | claimed |
| EP-4525926-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | claimed |
| EP-4525928-A1 | ANTIBODY DRUG CONJUGATES | Novartis AG (CH) | 2025-03-26 | — | — | EP | claimed |
| WO-2024189481-A1 | PANRAS INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2024-09-19 | — | — | WO | claimed |
| US-20240269304-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | LES LABORATOIRES SERVIER (FR) | 2024-08-15 | — | — | US | claimed |
| WO-2023225359-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | claimed |
| WO-2023225336-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | claimed |
| WO-2023223097-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | claimed |
| WO-2023225320-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | claimed |
| EP-4251209-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2023-10-04 | — | — | EP | claimed |
| US-20230092679-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-23 | — | — | US | claimed |
| WO-2022115477-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | claimed |
| EP-3972651-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | claimed |
| WO-2020236825-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092679-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, BCL9, BAK1 | CA2 4800/4885CA1 3686/4885CA12 3785/4885 |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPHA2, EPHA1, EPHB1 | CA2 1668/4885CA1 362/4885CA12 811/4885 |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | BID, BCL2, MCL1 | CA2 1857/4885CA1 1911/4885CA12 606/4885 |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | MET, BCL3, BCL9 | CA2 3647/4885CA1 1585/4885CA12 1485/4885 |
| US-20240269304-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | BCL3, BCL9, BCL2L10 | CA2 4016/4885CA1 1664/4885CA12 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.